Statistics for Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Total visits
| views | |
|---|---|
| Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) | 184 |
Total visits per month
| views | |
|---|---|
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
File Visits
| views | |
|---|---|
| nihms897429.pdf | 267 |
Top country views
| views | |
|---|---|
| United States | 135 |
| Germany | 8 |
| Ukraine | 8 |
| United Kingdom | 3 |
| Canada | 2 |
| Vietnam | 2 |
| Switzerland | 1 |
| Chile | 1 |
| China | 1 |
| Czechia | 1 |
| France | 1 |
| Iran | 1 |
| Malaysia | 1 |
| Russia | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 54 |
| Fairfield | 16 |
| White Plains | 11 |
| Houston | 9 |
| Kiev | 8 |
| Jacksonville | 6 |
| Kiez | 6 |
| Cambridge | 5 |
| Chicago | 3 |
| Ann Arbor | 2 |
| Baltimore | 2 |
| Dong Ket | 2 |
| Gunzenhausen | 2 |
| Toronto | 2 |
| Beijing | 1 |
| Brooklyn | 1 |
| Courbevoie | 1 |
| Lausanne | 1 |
| Norwalk | 1 |
| San Francisco | 1 |
| Santiago | 1 |
| Scottsdale | 1 |
| Seattle | 1 |
| Seremban | 1 |
| Slapanice | 1 |
| Stockholm | 1 |
| Tehran | 1 |